RenovoRx (RNXT) Amortization of Deferred Charges (2021 - 2025)

RenovoRx (RNXT) posted Amortization of Deferred Charges of $23000.0 for Q3 2025, up 15.0% sequentially from $20000.0 in Q2 2025.

RenovoRx (RNXT) Amortization of Deferred Charges (2021 - 2025) Analysis & Trends

RenovoRx has reported Amortization of Deferred Charges for 2 years, with the latest figure at $23000.0 in Q3 2025.

Quarterly Amortization of Deferred Charges changed N/A year-over-year to $23000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $65000.0 (changed N/A YoY) and the FY2021 annual result came in at $697000.0, up 5708.33% from the prior year.
Amortization of Deferred Charges grew to $23000.0 in Q3 2025 per RNXT's latest filing, from $20000.0 in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at $533000.0 in Q2 2021 and troughed at $5000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	RenovoRx	62.20 Mn	62.20 Mn	766,000.00

Download Data